Novel therapeutics for the treatment of metastatic melanoma

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Metastatic malignant melanoma is an incurable disease with a median survival of 8.5 months and a probability of surviving 5 years after the diagnosis of less than 5%. To date, no systemic therapy has meaningfully changed these survival end points. Currently, in the USA the FDA has approved three agents for the treatment of metastatic melanoma: hydroxyurea, dacarbazine and interleukin-2. None of these have demonstrated a meaningfully prolonged survival of patients with metastatic melanoma. Therefore, a number of innovative therapeutic strategies have been pursued to improve outcomes, including immune therapy, tyrosine kinase inhibitors and angiogenesis inhibitors. Herein, we review some of the recent advances in novel therapeutic developments for the treatment of metastatic melanoma.

Original languageEnglish (US)
Pages (from-to)543-557
Number of pages15
JournalFuture Oncology
Issue number4
StatePublished - Sep 10 2009


  • Angiogenesis inhibitors
  • Immunotherapy
  • Metastatic melanoma
  • Novel therapeutics
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Novel therapeutics for the treatment of metastatic melanoma'. Together they form a unique fingerprint.

Cite this